A Phase II Study of the Dual mTOR Inhibitor MLN0128 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Authors :: Karen A. Autio
Gregory Shelkey
Melanie Hullings
Mia DeNunzio
Dana E. Rathkopf
Anthony Delacruz
Howard I. Scher
Katherine Pisano
Susan F. Slovin
Michael J. Morris
Source :: Journal of Clinical Oncology. 34:e16529-e16529
Publication Year :: 2016
Publisher :: American Society of Clinical Oncology (ASCO), 2016.
Abstract: e16529Background: MLN0128 is a first-in-class, dual mTOR inhibitor that has the potential to overcome resistance seen with standard rapalogs through inhibition of both TORC1 and TORC2. This phase I...

Subjects :: 0301 basic medicine
Cancer Research
business.industry
Phases of clinical research
Castration resistant
Discovery and development of mTOR inhibitors
medicine.disease
03 medical and health sciences
Prostate cancer
030104 developmental biology
0302 clinical medicine
Oncology
030220 oncology & carcinogenesis
medicine
Cancer research
In patient
business

Full Text Access

Tools